You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

230 Results
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Regimen
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Apr 2023
Regimen
Intent: Palliative
Apr 2023
Regimen
Intent: Palliative
Apr 2023
Regimen
Intent: Palliative
Oct 2022
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB Limited Use
    lenalidomide - For the maintenance treatment of patients with newly diagnosed multiple myeloma, following ASCT, according to clinical criteria
May 2022
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Apr 2022

Pages